biotech
Amgen Seeks Banning of Roche's Anemia Drug, Cera
Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics , Patents and Intellectual Property Rights by ruth on April 12, 2006
Amgen Seeks Banning of Roche's Anemia Drug, Cera
Biopharmaceutical giant Amgen has filed a claim with the US International Trade Commission requesting for a ban on imports of an experimental anemia drug called Cera, manufactured by Roche. According to Amgen, Roche's manufacturing protocol infringes Amgen's patents covering its own anemia drug, Epogen. Roche denies this, arguing that
its pegylated version of EPO does not infringe Amgen's patents because it is linked to a chemical that makes it last longer in the body than Epogen, which Amgen sells in the United States as a treatment for anemia in patients on kidney dialysis.


According to a Reuters article, Roche's Cera has not yet been approved for sale in the US or in Europe. Amgen is hopeful that the ITC will launch a formal investigation which might take months to complete, considering that Amgen is seeking a "permanent exclusion order." Meanwhile, Roche will continue to file marketing applications worldwide.


Permalink: Amgen Seeks Banning of Roche's Anemia Drug, Cera
Tags: anemia  patent  amgen  biotech  roche  anemia+drug  roche+anemia  amgen+seeks 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/19963
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Amgen Seeks Banning of Roche's Anemia Drug, Cera:

  • Currently 5.67/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 5.67 out of 6 vote(s) cast.
Subscribe
Share It
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!